In a report released today, Mitchell Kapoor from H.C. Wainwright reiterated a Buy rating on Alumis Inc. (ALMS – Research Report), with a price ...

Alumis Inc.'s twice-a-day oral drug totally cleared the skin of telltale red, itchy patches in nearly 39% of 80 ...

Acelyrin has declined a surprise offer from Concentra Biosciences, and is instead p | Acelyrin consulted with independent ...

Acelyrin (NASDAQ:SLRN) announced Thursday a decision to adopt a limited-duration stockholder rights plan, also known as a poison pill, after Tang Capital Partners rapidly accumulated 8.8% of the ...

A live webcast will be available on the Alumis website in the "Investors" section under the “Events” page.

Acelyrin and Alumis plan to close their merger in the second quarter of 2025, pending clearances and shareholder approval.

HC Wainwright reissued their buy rating on shares of Alumis (NASDAQ:ALMS – Free Report) in a report published on Monday,Benzinga reports. They currently have a $19.00 price objective on the stock. A ...

Patients treated with ESK-001 for moderate to severe plaque psoriasis experienced positive clinical responses through a year, ...

While the job market is tough for life sciences professionals right now, it won’t always be. Employers must continue striving ...

Alumis announced positive Phase 2 OLE results for ESK-001, a TYK2 inhibitor for moderate-to-severe plaque psoriasis, showing sustained clinical improvements. Alumis Inc. has announced positive 52 ...

Alumis Inc. SOUTH SAN FRANCISCO, Calif., March 10, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing oral therapies using a precision ...